Amarin Corporation (AMRN) Proxy Filing summary

Executive summary

• 2024 focused on leadership transition, new CEO appointment, and a sharpened commercial strategy in Europe, with continued U.S. profitability and global expansion efforts for VASCEPA/VAZKEPA.

• Ended 2024 with over $200 million in revenue, $294 million in cash, and no debt, but share price momentum lagged despite operational progress.

• Priorities for 2025 include accelerating European growth, maintaining U.S. profitability, supporting research, and prudent cash management.

Voting matters and shareholder proposals

• Shareholders will vote on the re-election of nine directors, an advisory say-on-pay vote, auditor appointment, authority to allot shares, and disapplication of pre-emptive rights.

• Board recommends voting FOR all director nominees and proposals.

• Only shareholders as of March 27, 2025, may vote; quorum requires at least two shareholders or one-third of outstanding shares present.

• Shareholder proposals for the 2026 AGM must be received by December 10, 2025, and director nominations require advance written notice.

Board of directors and corporate governance

• Board restructured in 2024; all directors now stand for annual re-election.

• Board is majority independent, with only the CEO classified as non-independent.

• Key committees (Audit, Remuneration, Nominating & Governance) are composed solely of independent directors.

• Code of Conduct updated in July 2024; robust shareholder communication channels in place.

• Directors and executives are subject to stock ownership guidelines and anti-hedging/pledging policies.